Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

Updates in the management of polycythemia vera and essential thrombocythemia.

Bose P, Verstovsek S.

Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. Review.

PMID:
31516686
2.

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.

Jette NR, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, Bose P, Bebb DG, Lees-Miller SP.

Br J Cancer. 2019 Sep 4. doi: 10.1038/s41416-019-0565-8. [Epub ahead of print]

PMID:
31481733
3.

Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Shen Y, Grisdale CJ, Islam SA, Bose P, Lever J, Zhao EY, Grinshtein N, Ma Y, Mungall AJ, Moore RA, Lun X, Senger DL, Robbins SM, Wang AY, MacIsaac JL, Kobor MS, Luchman HA, Weiss S, Chan JA, Blough MD, Kaplan DR, Cairncross JG, Marra MA, Jones SJM.

Proc Natl Acad Sci U S A. 2019 Aug 30. pii: 201813495. doi: 10.1073/pnas.1813495116. [Epub ahead of print]

PMID:
31471491
4.

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S.

Blood Adv. 2019 Aug 13;3(15):2264-2271. doi: 10.1182/bloodadvances.2019000152.

5.

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.

Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG.

Br J Haematol. 2019 Jul 25. doi: 10.1111/bjh.16117. [Epub ahead of print] No abstract available.

PMID:
31344256
6.

The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis.

Bose P, Tremblay E, Maois C, Narasimhan V, Armstrong GAB, Liao M, Parker JA, Robitaille R, Wen XY, Barden C, Drapeau P.

Neurotherapeutics. 2019 Jul 24. doi: 10.1007/s13311-019-00765-w. [Epub ahead of print]

PMID:
31342410
7.

Sero-Occurrence of HBV/HCV Co-infection and Levels of Liver Enzymes among Patients at a Tertiary Care Hospital in Central India: a Pilot Study.

Desikan P, Rangnekar A, Khan Z, Panwalkar N, Bose P, Gulwani HV, Kaur S.

Cent Asian J Glob Health. 2019 Mar 29;8(1):313. doi: 10.5195/cajgh.2019.313. eCollection 2019.

8.

MoS2-Modified Curcumin Nanostructures: The Novel Theranostic Hybrid Having Potent Antibacterial and Antibiofilm Activities against Multidrug-Resistant Hypervirulent Klebsiella pneumoniae.

Singh AK, Mishra H, Firdaus Z, Yadav S, Aditi P, Nandy N, Sharma K, Bose P, Pandey AK, Chauhan BS, Neogi K, Vikram K, Srivastava A, Kar AG, Prakash P.

Chem Res Toxicol. 2019 Aug 19;32(8):1599-1618. doi: 10.1021/acs.chemrestox.9b00135. Epub 2019 Jul 31.

PMID:
31315397
9.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Jul 16. doi: 10.1002/cncr.32387. [Epub ahead of print]

PMID:
31310323
10.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.

Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS.

Am J Clin Oncol. 2019 Aug;42(8):649-654. doi: 10.1097/COC.0000000000000567.

PMID:
31305287
11.

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR.

Haematologica. 2019 Jul 11. pii: haematol.2019.223503. doi: 10.3324/haematol.2019.223503. [Epub ahead of print]

12.

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.

Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG.

Br J Haematol. 2019 Jun 26. doi: 10.1111/bjh.16042. [Epub ahead of print]

PMID:
31243771
13.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
14.

The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Masarova L, Bose P, Verstovsek S.

Curr Hematol Malig Rep. 2019 Aug;14(4):310-327. doi: 10.1007/s11899-019-00527-7. Review.

PMID:
31228096
15.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
16.

Frontal assessment battery in Parkinson's disease: A study on 170 patients.

Datta AK, Das D, Bhattacharyya KB, Bose P, Mishra AK, Das SK.

Neurol India. 2019 Mar-Apr;67(2):433-438. doi: 10.4103/0028-3886.258052.

17.

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.

Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA.

Hematol Oncol. 2019 Aug;37(3):240-252. doi: 10.1002/hon.2622. Epub 2019 Jun 20. Review.

PMID:
31013548
18.

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.

Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG.

Br J Haematol. 2019 Jun;185(5):852-864. doi: 10.1111/bjh.15877. Epub 2019 Mar 28.

PMID:
30924136
19.

A new "angle" on aortic neck angulation measurement.

Rockley M, Hadziomerovic A, van Walraven C, Bose P, Scallan O, Jetty P.

J Vasc Surg. 2019 Sep;70(3):756-761.e1. doi: 10.1016/j.jvs.2018.11.036. Epub 2019 Mar 2.

PMID:
30837183
20.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S.

Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.

PMID:
30811597
21.

Effect of transport temperature on the viability of Mycobacterium tuberculosis.

Desikan P, Panwalkar N, Bose P, Ansari K.

Indian J Tuberc. 2019 Jan;66(1):1-2. doi: 10.1016/j.ijtb.2018.06.008. Epub 2018 Aug 21. No abstract available.

PMID:
30797264
22.

Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.

Bose P, Chen LS, Gandhi V.

Leuk Lymphoma. 2019 Jul;60(7):1603-1605. doi: 10.1080/10428194.2019.1571207. Epub 2019 Feb 6. No abstract available.

PMID:
30724681
23.

New Concepts of Treatment for Patients with Myelofibrosis.

Bose P, Alfayez M, Verstovsek S.

Curr Treat Options Oncol. 2019 Jan 24;20(1):5. doi: 10.1007/s11864-019-0604-y. Review.

PMID:
30675650
24.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN.

Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.

25.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):142-148.e1. doi: 10.1016/j.clml.2018.12.009. Epub 2018 Dec 20.

PMID:
30635233
26.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2019 Jul;60(7):1767-1774. doi: 10.1080/10428194.2018.1543876. Epub 2019 Jan 11.

PMID:
30632841
27.

Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.

Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M, Goadsby PJ.

Brain. 2019 Jan 1;142(1):103-119. doi: 10.1093/brain/awy313.

28.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21.

PMID:
30575820
29.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088.

PMID:
30545997
30.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F.

Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10.

PMID:
30545576
31.

Extraction of levetiracetam for therapeutic drug monitoring by transdermal reverse iontophoresis.

Giri TK, Ghosh B, Bose P, Saha S, Sarkar A.

Eur J Pharm Sci. 2019 Feb 1;128:54-60. doi: 10.1016/j.ejps.2018.11.020. Epub 2018 Nov 20.

PMID:
30468869
32.

Neuromuscular junction abnormalities in a zebrafish loss-of-function model of TDP-43.

Bose P, Armstrong GAB, Drapeau P.

J Neurophysiol. 2019 Jan 1;121(1):285-297. doi: 10.1152/jn.00265.2018. Epub 2018 Nov 21.

PMID:
30461368
33.

Wireless Channel Modeling for Leadless Cardiac Pacemaker: Effects ofVentricular Blood Volume.

Bose P, Khaleghi A, Balasingham I.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:3746-3749. doi: 10.1109/EMBC.2018.8513099.

PMID:
30441181
34.

Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis.

Kumar P, Bose PP.

Drug Deliv Transl Res. 2019 Feb;9(1):249-259. doi: 10.1007/s13346-018-00602-1.

PMID:
30430452
35.

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure.

Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD.

Nat Commun. 2018 Nov 8;9(1):4692. doi: 10.1038/s41467-018-06654-8.

36.

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.

Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15.

PMID:
30328139
37.

Microglia induces Gas1 expression in human brain tumor-initiating cells to reduce tumorigenecity.

Sarkar S, Poon CC, Mirzaei R, Rawji KS, Hader W, Bose P, Kelly J, Dunn JF, Yong VW.

Sci Rep. 2018 Oct 16;8(1):15286. doi: 10.1038/s41598-018-33306-0.

38.

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.

Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

39.

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.

Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, Chan TA, Klimstra DS, Allis CD, Tang LH.

Nat Commun. 2018 Oct 12;9(1):4158. doi: 10.1038/s41467-018-06498-2.

40.

Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.

Mirzaei R, Sarkar S, Dzikowski L, Rawji KS, Khan L, Faissner A, Bose P, Yong VW.

Oncoimmunology. 2018 Aug 6;7(10):e1478647. doi: 10.1080/2162402X.2018.1478647. eCollection 2018.

41.

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V.

Blood. 2018 Nov 22;132(21):2249-2259. doi: 10.1182/blood-2018-06-860593. Epub 2018 Sep 25.

PMID:
30254130
42.

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.

Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. No abstract available.

PMID:
30242087
43.

Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways.

Pattanayak SP, Bose P, Sunita P, Siddique MUM, Lapenna A.

Biomed Pharmacother. 2018 Dec;108:297-308. doi: 10.1016/j.biopha.2018.08.145. Epub 2018 Sep 15.

44.

Longitudinal Examination of Bone Loss in Male Rats After Moderate-Severe Contusion Spinal Cord Injury.

Otzel DM, Conover CF, Ye F, Phillips EG, Bassett T, Wnek RD, Flores M, Catter A, Ghosh P, Balaez A, Petusevsky J, Chen C, Gao Y, Zhang Y, Jiron JM, Bose PK, Borst SE, Wronski TJ, Aguirre JI, Yarrow JF.

Calcif Tissue Int. 2019 Jan;104(1):79-91. doi: 10.1007/s00223-018-0471-8. Epub 2018 Sep 14.

PMID:
30218117
45.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

46.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
47.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
48.

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA.

Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.

49.

The Migraine Postdrome.

Bose P, Karsan N, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1023-1031. doi: 10.1212/CON.0000000000000626. Review.

PMID:
30074547
50.

The Migraine Premonitory Phase.

Karsan N, Bose P, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):996-1008. doi: 10.1212/CON.0000000000000624. Review.

PMID:
30074545

Supplemental Content

Support Center